IPO Trending
SYMBIOTECEQ / NSE, BSEUpcoming

Symbiotec Pharmalab Limited

Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company that develops and manufactures active pharmaceutical ingredients, nutritional ingredients, and specialty products for both domestic and international markets. The company focuses on research-based manufacturing, strong quality standards, and sustainable processes, serving industries like pharmaceuticals, nutraceuticals, and wellness with high-quality and innovative products. With over 30 years of experience, it has grown from a small lab-scale steroid API manufacturer into a large, fully integrated company with approvals from global authorities like the US FDA, EU-GMP, and Korea’s Ministry of Food and Drug Safety. As of June 30, 2025, the company operates two large-scale manufacturing facilities with a chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.

₹0 - ₹0GMP ₹0Open
GMPFlat
Est. Listing Price₹0
FinancialsBalance sheet and operational figures in Crores
Metric Breakdown

Revenue

Latest (Jun-25)205.81 Cr
Growth-64.1%
Revenue Trend (₹ in Crores)
0.0289.8579.6869.4Mar-23Mar-24Mar-25Jun-25
PeriodRev (Cr)PAT (Cr)AssetsDebt
Jun-25205.8129.921,598.34519.12
Mar-25755.9896.791,579.65540.92
Mar-24723.33100.061,294.79247.21
Mar-23572.9723.49989.99217.88
Key Performance Indicators (KPIs)
PeriodEPSROEROCEP/E (Pre)P/E (Post)
Mar-25012.66%11.80%34.470